Ratios Uncovered: Breaking Down 4D Molecular Therapeutics Inc (FDMT)’s Trailing Twelve Months Metrics

The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

The price of 4D Molecular Therapeutics Inc (NASDAQ: FDMT) closed at $13.50 in the last session, down -19.74% from day before closing price of $16.82. In other words, the price has decreased by -$19.74 from its previous closing price. On the day, 3.36 million shares were traded. FDMT stock price reached its highest trading level at $17.41 during the session, while it also had its lowest trading level at $12.48.

Ratios:

We take a closer look at FDMT’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 28.48 and its Current Ratio is at 28.48. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.02.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Barclays on April 15, 2024, initiated with a Overweight rating and assigned the stock a target price of $459.

On April 15, 2024, Barclays started tracking the stock assigning a Overweight rating and target price of $45.

Insider Transactions:

An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Sep 16 ’24 when Bizily Scott sold 500 shares for $16.33 per share. The transaction valued at 8,165 led to the insider holds 6,781 shares of the business.

Bizily Scott sold 500 shares of FDMT for $7,500 on Aug 19 ’24. The Chief Legal Officer now owns 6,781 shares after completing the transaction at $15.00 per share. On Jul 16 ’24, another insider, Bizily Scott, who serves as the Chief Legal Officer of the company, sold 1,750 shares for $27.11 each. As a result, the insider received 47,442 and left with 6,781 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, FDMT now has a Market Capitalization of 872569792 and an Enterprise Value of 173299472. For the stock, the TTM Price-to-Sale (P/S) ratio is 31.91 while its Price-to-Book (P/B) ratio in mrq is 1.19. Its current Enterprise Value per Revenue stands at 8.572 whereas that against EBITDA is -1.367.

Stock Price History:

Over the past 52 weeks, FDMT has reached a high of $36.25, while it has fallen to a 52-week low of $9.44. The 50-Day Moving Average of the stock is -19.80%, while the 200-Day Moving Average is calculated to be -39.36%.

Shares Statistics:

According to the various share statistics, FDMT traded on average about 881.78K shares per day over the past 3-months and 838460 shares per day over the past 10 days. A total of 51.97M shares are outstanding, with a floating share count of 43.73M. Insiders hold about 15.85% of the company’s shares, while institutions hold 105.37% stake in the company. Shares short for FDMT as of 1724976000 were 9873630 with a Short Ratio of 11.20, compared to 1722384000 on 9530709. Therefore, it implies a Short% of Shares Outstanding of 9873630 and a Short% of Float of 19.680001.

Most Popular